Dermapharm Holding SE expects the cooperation with BioNTech SE in vaccine production to make a high double-digit million - contribution to sales in 2021
Disclosure of Insider Information pursuant to Section 17 (1) 1 of the Regulation (EU) No. 596/2014 on Market Abuse, as amended (Market Abuse Regulation - MAR)
Dermapharm Holding SE expects the cooperation with BioNTech SE in vaccine production to make a high double-digit million ? contribution to sales in 2021
Gr?nwald, February 12, 2021 - Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) expects the cooperation with BioNTech SE, Mainz, in the production of the Covid-19 vaccine Comirnaty(R) to contribute a high double-digit million ? amount to the consolidated sales of the Dermapharm Group in the full year 2021. This is the result of a current plan for vaccine production approved today by the Management Board of Dermapharm Holding SE. Among other things, it includes the establishment of additional production capacities at the Reinbek site, which are scheduled to go into operation in May 2021.
>End of the ad hoc announcement< Contacts
Investor Relations & Corporate Communications Britta Hamberger Phone: +49 (0)89 - 64186-233 Fax: +49 (0)89 - 64186-165 e-Mail: email@example.com cometis AG Claudius Krause Phone: +49 (0)611 - 205855-28 Fax: +49 (0)611 - 205855-66 e-Mail: firstname.lastname@example.org ?
12-Feb-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.deLanguage: English Company: Dermapharm Holding SE Lil-Dagover-Ring 7 82031 Gr?nwald
Germany Phone: +49 (0)89 64 86-0 E-mail: email@example.com Internet: ir.dermapharm.de ISIN: DE000A2GS5D8 WKN: A2GS5D Indices: SDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange EQS News ID: 1167965 ? End of Announcement DGAP News Service